amiodarone has been researched along with Chagas Disease in 18 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Chagas Disease: Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Accordingly, amiodarone, an inexpensive and extensively- used class III antiarrhythmic has been proposed as a treatment for Chagas' disease and leishmaniasis." | 8.02 | The Rationale for Use of Amiodarone and its Derivatives for the Treatment of Chagas' Disease and Leishmaniasis. ( Benaim, G; Paniz-Mondolfi, AE; Sordillo, EM, 2021) |
| "4 mg/lb], PO, q 24 h, with or without a loading dosage protocol) and itraconazole (approx 10 mg/kg [4." | 5.51 | Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. ( Benaím, G; Estep, JS; Luis Concepción, J; Madigan, R; Majoy, S; Márquez, ME; Mogollón-Mendoza, AC; Paniz-Mondolfi, AE; Pérez Alvarez, A; Ritter, K; Rodriguez-Morales, AJ; Silva, SC; Zao, CL, 2019) |
| " We compared 72 patients with long-term use (11 +/- 5 years) of amiodarone, including 22 patients who developed goiter, to 33 patients who did not use amiodarone, followed-up for 2 to 20 years (7 +/- 11 years)." | 5.32 | Impact of long-term administration of amiodarone on the thyroid function of patients with Chagas' disease. ( Fernandes, GA; Guariento, ME; Maciel, RM; Silva, JR; Ward, LS, 2004) |
| " Accordingly, amiodarone, an inexpensive and extensively- used class III antiarrhythmic has been proposed as a treatment for Chagas' disease and leishmaniasis." | 4.02 | The Rationale for Use of Amiodarone and its Derivatives for the Treatment of Chagas' Disease and Leishmaniasis. ( Benaim, G; Paniz-Mondolfi, AE; Sordillo, EM, 2021) |
| " Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10) serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and arrhythmias." | 3.85 | Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status. ( Fresno, M; Gironès, N; Marques, J; Mendoza, I; Mijares, A; Rodríguez-Angulo, H; Villegas, M, 2017) |
| "Amiodarone is also capable to inhibit the oxidosqualene cyclase, a key enzyme in the synthesis of ergosterol." | 2.47 | Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. ( Benaim, B; Garcia, CR, 2011) |
| "4 mg/lb], PO, q 24 h, with or without a loading dosage protocol) and itraconazole (approx 10 mg/kg [4." | 1.51 | Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. ( Benaím, G; Estep, JS; Luis Concepción, J; Madigan, R; Majoy, S; Márquez, ME; Mogollón-Mendoza, AC; Paniz-Mondolfi, AE; Pérez Alvarez, A; Ritter, K; Rodriguez-Morales, AJ; Silva, SC; Zao, CL, 2019) |
| "Chagas disease is a neglected tropical affection caused by the protozoan parasite Trypanosoma cruzi." | 1.48 | Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure. ( Benaim, G; Hejchman, E; Hernández-Rodríguez, V; Pinto-Martinez, A; Rodríguez-Durán, J, 2018) |
| "Dronedarone is an amiodarone derivative in which the 2,5-diiodophenyl moiety of the parental drug has been replaced with an unsubstituted phenyl group aiming to eliminate the thyroid toxicity frequently observed with amiodarone treatment." | 1.38 | In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. ( Benaim, G; Garcia-Marchan, Y; Hernandez-Rodriguez, V; Mujica-Gonzalez, S; Paniz-Mondolfi, A; Parra-Gimenez, N; Plaza-Rojas, L; Silva, ML; Uzcanga, G, 2012) |
| "Stroke was more frequent in CD (15." | 1.33 | Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort. ( Faiçal, F; Oliveira-Filho, J; Reis, FJ; Torreão, JA; Viana, LC; Vieira-de-Melo, RM; Villar, FA, 2005) |
| " We compared 72 patients with long-term use (11 +/- 5 years) of amiodarone, including 22 patients who developed goiter, to 33 patients who did not use amiodarone, followed-up for 2 to 20 years (7 +/- 11 years)." | 1.32 | Impact of long-term administration of amiodarone on the thyroid function of patients with Chagas' disease. ( Fernandes, GA; Guariento, ME; Maciel, RM; Silva, JR; Ward, LS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Benaim, G | 6 |
| Sanders, JM | 1 |
| Garcia-Marchán, Y | 2 |
| Colina, C | 1 |
| Lira, R | 1 |
| Caldera, AR | 1 |
| Payares, G | 1 |
| Sanoja, C | 1 |
| Burgos, JM | 1 |
| Leon-Rossell, A | 1 |
| Concepcion, JL | 2 |
| Schijman, AG | 1 |
| Levin, M | 1 |
| Oldfield, E | 1 |
| Urbina, JA | 1 |
| Engel, JC | 1 |
| Ang, KK | 1 |
| Chen, S | 1 |
| Arkin, MR | 1 |
| McKerrow, JH | 1 |
| Doyle, PS | 1 |
| Barbosa, JMC | 2 |
| Pedra Rezende, Y | 1 |
| de Melo, TG | 2 |
| de Oliveira, G | 1 |
| Cascabulho, CM | 1 |
| Pereira, ENGDS | 1 |
| Daliry, A | 2 |
| Salem, KS | 1 |
| Pedra-Rezende, Y | 1 |
| Pereira, LD | 1 |
| Barbosa, HS | 1 |
| Lannes-Vieira, J | 1 |
| de Castro, SL | 1 |
| Salomão, K | 1 |
| Paniz-Mondolfi, AE | 4 |
| Sordillo, EM | 2 |
| Martinez-Sotillo, N | 1 |
| Rodríguez-Angulo, H | 1 |
| Marques, J | 1 |
| Mendoza, I | 1 |
| Villegas, M | 1 |
| Mijares, A | 1 |
| Gironès, N | 1 |
| Fresno, M | 1 |
| Pinto-Martinez, A | 1 |
| Hernández-Rodríguez, V | 2 |
| Rodríguez-Durán, J | 1 |
| Hejchman, E | 1 |
| Madigan, R | 2 |
| Majoy, S | 1 |
| Ritter, K | 1 |
| Luis Concepción, J | 1 |
| Márquez, ME | 1 |
| Silva, SC | 1 |
| Zao, CL | 2 |
| Pérez Alvarez, A | 1 |
| Rodriguez-Morales, AJ | 1 |
| Mogollón-Mendoza, AC | 1 |
| Estep, JS | 1 |
| Yang, YC | 1 |
| Tomanek, L | 1 |
| Cooke, A | 1 |
| Berger, R | 1 |
| Chien, LC | 1 |
| Carmo, AA | 1 |
| Rocha, MO | 1 |
| Silva, JL | 1 |
| Ianni, BM | 1 |
| Fernandes, F | 1 |
| Sabino, EC | 1 |
| Ribeiro, AL | 1 |
| Bestetti, R | 1 |
| Cardinalli-Neto, A | 1 |
| Pérez-Alvarez, AM | 1 |
| Lanza, G | 1 |
| Márquez, E | 1 |
| Benaim, B | 1 |
| Garcia, CR | 1 |
| Mujica-Gonzalez, S | 1 |
| Plaza-Rojas, L | 1 |
| Silva, ML | 1 |
| Parra-Gimenez, N | 1 |
| Paniz-Mondolfi, A | 1 |
| Uzcanga, G | 1 |
| Silva, JR | 1 |
| Guariento, ME | 1 |
| Fernandes, GA | 1 |
| Maciel, RM | 1 |
| Ward, LS | 1 |
| Oliveira-Filho, J | 1 |
| Viana, LC | 1 |
| Vieira-de-Melo, RM | 1 |
| Faiçal, F | 1 |
| Torreão, JA | 1 |
| Villar, FA | 1 |
| Reis, FJ | 1 |
| Leite, SA | 1 |
| Leite, PJ | 1 |
| Rocha, GA | 1 |
| Routledge, PA | 1 |
| Bittencourt, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Trial Testing Amiodarone in Chagas Cardiomyopathy (ATTACH)[NCT03193749] | Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amiodarone and Chagas Disease
| Article | Year |
|---|---|
Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against
Topics: Amiodarone; Calcium; Chagas Disease; Homeostasis; Humans; Trypanosoma cruzi | 2020 |
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishman | 2011 |
1 trial available for amiodarone and Chagas Disease
| Article | Year |
|---|---|
Carbamazepine kinetics in cardiac patients before and during amiodarone.
Topics: Adult; Aged; Amiodarone; Carbamazepine; Chagas Disease; Drug Interactions; Drug Therapy, Combination | 1994 |
15 other studies available for amiodarone and Chagas Disease
| Article | Year |
|---|---|
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
Topics: Acute Disease; Amiodarone; Animals; Calcium; Chagas Disease; Chlorocebus aethiops; Crystallography, | 2006 |
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Topics: Animals; Cattle; Cell Line; Cell Line, Tumor; Chagas Disease; Drug Evaluation, Preclinical; Hepatocy | 2010 |
Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
Topics: Amiodarone; Animals; Chagas Disease; Disease Models, Animal; Drug Therapy, Combination; Heart; Heart | 2022 |
Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in
Topics: Amiodarone; Chagas Disease; Cytoskeleton; Humans; Nitroimidazoles; Trypanocidal Agents; Trypanosoma | 2022 |
The Rationale for Use of Amiodarone and its Derivatives for the Treatment of Chagas' Disease and Leishmaniasis.
Topics: Amiodarone; Animals; Calcium; Chagas Disease; Dogs; Leishmaniasis; Trypanocidal Agents; Trypanosoma | 2021 |
Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Arrhythmias, Cardiac; Biomarkers; Chagas Disease; Cyt | 2017 |
Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure.
Topics: Amiodarone; Animals; Benzofurans; Calcium; Chagas Disease; Chlorocebus aethiops; Dose-Response Relat | 2018 |
Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs.
Topics: Amiodarone; Animals; Chagas Disease; Dog Diseases; Dogs; Itraconazole; Louisiana; Texas; Trypanosoma | 2019 |
PCR monitoring of parasitemia during drug treatment for canine Chagas disease.
Topics: Amiodarone; Animals; Chagas Disease; DNA, Kinetoplast; DNA, Protozoan; DNA, Satellite; Dog Diseases; | 2019 |
Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Chagas Disease; Female; Humans; Male; Middle Aged; Parasi | 2015 |
Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; | 2009 |
Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Disease; Chronic Disease; Drug Therapy, Combinat | 2009 |
In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.
Topics: Amiodarone; Calcium; Chagas Disease; Dronedarone; Membrane Potential, Mitochondrial; Trypanosoma cru | 2012 |
Impact of long-term administration of amiodarone on the thyroid function of patients with Chagas' disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chagas Disease; Echocardiography; Electrocardiography; Electroca | 2004 |
Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Chagas Disease; Cohort Studies; Fem | 2005 |